<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurol</journal-id><journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id><journal-title-group><journal-title>Frontiers in Neurology</journal-title></journal-title-group><issn pub-type="epub">1664-2295</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40401017</article-id><article-id pub-id-type="pmc">PMC12092212</article-id><article-id pub-id-type="doi">10.3389/fneur.2025.1555068</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neurology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Real world study in Italian public hospital with Efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sgarzi</surname><given-names>Manlio</given-names></name><xref rid="fn0001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Paone</surname><given-names>Paolo</given-names></name><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><xref rid="fn0002" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2938423/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Camera</surname><given-names>Giorgia</given-names></name><xref rid="fn0003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Agazzi</surname><given-names>Emanuela</given-names></name><xref rid="fn0004" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Mazzoleni</surname><given-names>Sara</given-names></name><xref rid="fn0003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Martorana</surname><given-names>Francesca</given-names></name><xref rid="fn0003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Alimonti</surname><given-names>Dario</given-names></name><xref rid="fn0005" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff><institution>ASST Papa Giovanni XXIII Hospital</institution>, <addr-line>Bergamo</addr-line>, <country>Italy</country></aff><author-notes><fn fn-type="edited-by" id="fn0006"><p>Edited by: Edoardo Malfatti, H&#x000f4;pitaux Universitaires Henri Mondor, France</p></fn><fn fn-type="edited-by" id="fn0007"><p>Reviewed by: Katherine Buzzard, Monash University, Australia</p><p>Roberta Bonomo, Kore University of Enna, Italy</p></fn><corresp id="c001">*Correspondence: Paolo Paone, <email>ppaone@asst-pg23.it</email></corresp><fn fn-type="other" id="fn0001"><p><sup>&#x02020;</sup>ORCID: Manlio Sgarzi, <ext-link xlink:href="https://orcid.org/0000-0002-6875-8542" ext-link-type="uri">orcid.org/0000-0002-6875-8542</ext-link></p></fn><fn fn-type="other" id="fn0002"><p>Paolo Paone, <ext-link xlink:href="https://orcid.org/0000-0002-1505-746X" ext-link-type="uri">orcid.org/0000-0002-1505-746X</ext-link></p></fn><fn fn-type="other" id="fn0003"><p>Giorgia Camera, <ext-link xlink:href="https://orcid.org/0009-0001-3361-9032" ext-link-type="uri">orcid.org/0009-0001-3361-9032</ext-link></p></fn><fn fn-type="other" id="fn0004"><p>Emanuela Agazzi, <ext-link xlink:href="https://orcid.org/0009-0005-9505-2739" ext-link-type="uri">orcid.org/0009-0005-9505-2739</ext-link></p></fn><fn fn-type="other" id="fn0005"><p>Dario Alimonti, <ext-link xlink:href="https://orcid.org/0000-0001-7964-6282" ext-link-type="uri">orcid.org/0000-0001-7964-6282</ext-link></p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1555068</elocation-id><history><date date-type="received"><day>03</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Sgarzi, Paone, Camera, Agazzi, Mazzoleni, Martorana and Alimonti.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Sgarzi, Paone, Camera, Agazzi, Mazzoleni, Martorana and Alimonti</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec id="sec1"><title>Background</title><p>Myasthenia gravis (MG) is an autoimmune neuromuscular disorder caused by IgG autoantibodies targeting the neuromuscular junction. Recycling of IgG is mediated by the neonatal Fc receptor (FcRn). Efgartigimod, an Fc fragment of human IgG1, has demonstrated efficacy in MG; however, the clinical characteristics of patients with the highest response remain unclear.</p></sec><sec id="sec2"><title>Methods</title><p>Twelve patients with AChR-positive generalized MG were treated with two cycles of Efgartigimod over 1&#x0202f;year, and nine patients completed a third cycle. Clinical evaluation was conducted using MG-ADL at four time points and QMG at the beginning and end of each cycle. MG-ADL and QMG scores were further subdivided into ocular (O), bulbar (B), and generalized (G) symptom subdomains, and patients were classified as predominantly ocular (pO), bulbar (pB), or generalized (pG) based on symptom prevalence.</p></sec><sec id="sec3"><title>Results</title><p>Significant improvements were observed in MG-ADL and QMG from baseline across all symptom subdomains. Baseline AChR antibody levels correlated with MG-ADL improvement (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.04). Thymectomized patients demonstrated superior outcomes, with MG-ADL improving by 62% versus 22% (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01) and QMG by 45% versus 3.5% (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01) during the first two cycles. Patients with pO symptoms responded less to therapy, with generalized symptoms contributing most to the minor response.</p></sec><sec id="sec4"><title>Discussion</title><p>Our findings suggest that patients with high baseline AChR antibody titers, previous thymectomy, and non-ocular symptom predominance respond better to Efgartigimod. These results underscore the need for larger studies to validate these observations and optimize patient selection.</p></sec></abstract><kwd-group><kwd>Myasthenia Gravis</kwd><kwd>Efgartigimod</kwd><kwd>Thymectomy</kwd><kwd>T cells</kwd><kwd>AChR</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="7"/><equation-count count="0"/><ref-count count="25"/><page-count count="10"/><word-count count="5799"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Neuromuscular Disorders and Peripheral Neuropathies</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><title>Introduction</title><p>Myasthenia gravis (MG) is an autoimmune disorder characterized by impaired neuromuscular transmission. As a prototypical B cell-mediated autoimmune disease, MG is caused by IgG autoantibodies with well-established pathogenic effects (<xref rid="ref1" ref-type="bibr">1</xref>). The half-life of circulating human IgG ranges between 3 and 4&#x0202f;weeks. This prolonged circulation is not solely dependent on synthesis but is largely attributed to continuous salvage and recycling mechanisms mediated by the neonatal Fc receptor (FcRn) (<xref rid="ref2" ref-type="bibr">2</xref>). FcRn, a molecule structurally similar to MHC class I, plays a pivotal role in maintaining IgG and albumin levels by preventing their lysosomal degradation. This recycling mechanism extends the half-life of IgG approximately fourfold compared to other immunoglobulins not recycled by FcRn, such as IgM or IgA. During cellular uptake, the Fc region of IgG binds to two FcRn molecules under acidic endosomal conditions. This interaction prevents lysosomal degradation, allowing IgGs to be recycled and released at physiological pH into the extracellular environment. Consequently, FcRn perpetuates the availability of autoantibodies in IgG-mediated diseases, including generalized myasthenia gravis (gMG). The presence of pathogenic autoantibodies is a hallmark of autoimmune disorders, especially for myasthenia gravis (MG). Current therapies, such as plasmapheresis, IVIG infusions, and other immunosuppressive agents, aim to reduce pathogenic antibodies. However, most of these therapies have broader mechanisms of action and significant side effects. In virtue of a better understanding of the molecular structure and its biological properties, FcRn has emerged as an interesting target in the treatment of myasthenia gravis and other autoimmune disorders, as it allows the reduction of autoantibodies by blocking FcRn. By blocking FcRn, the catabolism of all subclass of IgG is inceased (<xref rid="fig1" ref-type="fig">Figure 1</xref>). This mechanism could be useful in various autoimmune disorders, as the degradation of IgG can be induced by blocking FcRn receptors, making it a rational therapeutic approach. Several drugs exploit this mechanism of action such as Rozanolixizumab, a human IgG4 anti-FcRn antibody, while Nipocalimab or Batoclimab, are fully humanized monoclonal antibodies of the IgG1 class (<xref rid="ref3" ref-type="bibr">3</xref>).</p><fig position="float" id="fig1"><label>Figure 1</label><caption><p>FcRn, Neonatal Fc receptor; IgG, immunoglobulin G. <bold>(A)</bold> FcRn is widely expressed on endothelial cells. IgG enters the cell via fluid-phase endocytosis. IgG bind to FcRn in acidic conditions (pH 6.0&#x02013;6.5) to form an IgG-FcRn complex (1). IgG that do not bind to FcRn in the acidified body are degraded in the lysosome (2). Under physiological conditions (extracellular compartment, pH 7.4), the IgG-FcRn complex dissociates at the cell surface and the IgG gets released again into the blood circulation (3). By this mechanism, FcRn efficiently safeguards IgG from lysosomal degradation, thus increasing the half-life of IgG. <bold>(B)</bold> FcRn inhibitors are monoclonal antibodies with higher affinity and an increased binding capacity to FcRn at neutral and acidic pH (1). Inside the cell, FcRn inhibitors compete with IgG for binding to FcRn, preventing IgG binding to FcRn. The unbound IgG enter the lysosomes where they are degraded (2). The process results in reduced IgG levels in the circulation, including the pathogenic IgG antibodies.</p></caption><graphic xlink:href="fneur-16-1555068-g001" position="float"/></fig><p>Efgartigimod (EFG), an Fc fragment of the human IgG1 antibody, has been engineered to exhibit greater affinity for FcRn than endogenous IgG, while retaining pH-dependent binding characteristics. By competitively binding to FcRn, Efgartigimod facilitates the degradation of unbound endogenous IgG in the acidic intracellular environment (<xref rid="ref4" ref-type="bibr">4</xref>). Efgartigimod has demonstrated efficacy across various MG subgroups and severity levels (<xref rid="ref5" ref-type="bibr">5</xref>), leading to its approval for managing gMG. Despite these advancements, the optimal dosage, duration of treatment, and identification of patient subpopulations most likely to benefit require further investigation. Here, we report our experience with the clinical efficacy and outcomes of Efgartigimod treatment in patients managed at a public hospital.</p></sec><sec sec-type="methods" id="sec6"><title>Method</title><p>The Expanded Access Program (EAP - version 1.0) was proposed with the logic of providing access to EFG to gMG patients before regulatory approval (GENERATIVE protocol version 1.0, September 10, 2021). All patients, after being adequately informed about the expected benefits and risks of the treatment, signed the informed consent before enrollment in the GENERATIVE program. The enrollment of each patient was possible after the approval of the EAP by the ethics committee of the ASST Papa Giovanni XXIII of Bergamo and subsequently the treatment with Efgartigimod was authorized by the Italian Medicines Agency with resolution in GU n.160 of 11-7-2023.</p><sec id="sec7"><title>Inclusion criteria</title><p>In GENERATIVE protocol procedures, the following inclusion criteria had to be met:</p><list list-type="roman-lower"><list-item><p>&#x0003e;&#x0202f;18&#x0202f;years at the time of signing the informed consent.</p></list-item><list-item><p>Patients diagnosed with MG (AChR-Ab seropositive or seronegative) with generalized muscle weakness supported by one of the following factors:</p><list list-type="alpha-lower"><list-item><p>Presence of AChR-Ab.</p></list-item><list-item><p>Abnormal neuromuscular transmission (single fiber or repeated stimulation).</p></list-item><list-item><p>History of positive Edrophonium Chloride test.</p></list-item><list-item><p>Demonstrated improvement in MG symptoms, after using oral anticholinesterase inhibitors.</p></list-item></list></list-item><list-item><p>Myasthenia Gravis Foundation of America (MGFA) Classification II, III, IVa or IVb (<xref rid="ref6" ref-type="bibr">6</xref>).</p></list-item><list-item><p>Total Myasthenia Gravis Activity of Daily Living (MG-ADL) score of &#x02265; 5 points, with &#x0003e; 50% of the total score attributed to non-ocular symptoms, or at least two non-ocular items had to have a score of &#x02265; 2.</p></list-item><list-item><p>Patient has been vaccinated against COVID-19 or had a negative COVID-19 test result within 2&#x0202f;weeks prior to enrollment.</p></list-item><list-item><p>Total IgG&#x0202f;&#x02265;&#x0202f;6&#x0202f;g/L within 1&#x0202f;month of screening.</p></list-item></list></sec><sec id="sec8"><title>Treatment</title><p>EFG was administered intravenously at a dose of 10&#x0202f;mg/kg as a 1-h infusion in cycles of four weekly infusions. The initial fixed period included two 3-weeks&#x0202f;cycles (four infusions per cycle T0-T1-T2-T3), each followed by a 4-weeks fixed wash-out period. Subsequently, in case of worsening of MG-ADL (<xref rid="ref7" ref-type="bibr">7</xref>) and Quantitative Myasthenia Gravis (QMG) (<xref rid="ref8" ref-type="bibr">8</xref>), patients could enter the flexible period at the discretion of the doctor, who could prescribe a new cycle of four infusions, always after a wash-out of at least 4&#x0202f;weeks, monitoring during the wash-out phase whether the clinical conditions were suitable, to prescribe further treatment. Throughout the period observed in this study, the pharmacological treatments of patients with non-steroidal immunosuppressants (NSIT), cholinesterase inhibitors and corticosteroids did not change.</p></sec><sec id="sec9"><title>Clinical evaluation of MG</title><p>Clinical evaluation was performed according to the following clinical scales specific for MG:</p><list list-type="bullet"><list-item><p>MG-ADL</p></list-item><list-item><p>QMG</p></list-item></list><p>MG-ADL scores were administered before each infusion in the first 3 administrations of each cycle and after the end of the last infusion of each cycle. The QMG score was recorded before the first and after the fourth infusion of each cycle. MG-ADL improvement was defined as a reduction of at least 2 points in the score; QMG improvement was defined as a reduction of at least 3 points in total QMG scores (<xref rid="ref1" ref-type="bibr">1&#x02013;4</xref>, <xref rid="ref9" ref-type="bibr">9</xref>, <xref rid="ref10" ref-type="bibr">10</xref>). An increase of at least 2 points for the MG-ADL score and 3 points for the QMG scores was considered clinical criterion for prescribing EFG retreatment during clinical follow-up in the flexible period. The improvements in MG-ADL and QMG were calculated by comparing the score of the last time point of each cycle (T3) with that recorded before the first infusion (T0), as a percentage. Furthermore, to obtain more specific data on the improvement obtained by patients before and after the different cycles of EFG infusion, we divided the total raw scores of MG-ADL and QMG into subclasses for specific symptoms (<xref rid="ref11" ref-type="bibr">11</xref>), Ocular (O), Bulbar (B) and Generalized (G), adding the scores of the relevant Items (<xref rid="tab1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><p>MG-ADL and QMG subdomains items.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Assessment</th><th align="left" valign="top" rowspan="1" colspan="1">Ocular items</th><th align="center" valign="top" rowspan="1" colspan="1">Possible score</th><th align="left" valign="top" rowspan="1" colspan="1">Bulbar items</th><th align="center" valign="top" rowspan="1" colspan="1">Possible score</th><th align="left" valign="top" rowspan="1" colspan="1">Generalized items</th><th align="center" valign="top" rowspan="1" colspan="1">Possible score</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">MG-ADL</td><td align="left" valign="top" rowspan="1" colspan="1">Diplopia, Ptosis</td><td align="center" valign="top" rowspan="1" colspan="1">0&#x02013;6</td><td align="left" valign="top" rowspan="1" colspan="1">Speech<break/>Swallowing<break/>Chewing</td><td align="center" valign="top" rowspan="1" colspan="1">0&#x02013;9</td><td align="left" valign="top" rowspan="1" colspan="1">Ability to brush<break/>Ability to arise<break/>Breathing</td><td align="center" valign="top" rowspan="1" colspan="1">0&#x02013;9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">QMG</td><td align="left" valign="top" rowspan="1" colspan="1">Diplopia Ptosis Facial muscles</td><td align="center" valign="top" rowspan="1" colspan="1">0&#x02013;9</td><td align="left" valign="top" rowspan="1" colspan="1">Speech Swallowing</td><td align="center" valign="top" rowspan="1" colspan="1">0&#x02013;6</td><td align="left" valign="top" rowspan="1" colspan="1">Hand Grip L/R<break/>Limb strength arms/legs<break/>Head lift<break/>Forced Vital Capacity</td><td align="center" valign="top" rowspan="1" colspan="1">0&#x02013;24</td></tr></tbody></table></table-wrap></sec><sec id="sec10"><title>Statistical analysis</title><p>Statistical analyses refer to the first three cycles of therapy with Efgartigimod, given the small number of the fourth cycle. Continuous variables were represented by Mean and Standard Deviation while categorical variables were represented by frequencies and percentages. The clinical efficacy of treatment with EFG for all patients in the study was verified by analyzing the mean of MG-ADL and QMG scores between the times of each cycle, we also verified the same means between T0 of the first cycle (baseline) and T3 of the second (1st-2nd Cycle) and third (1st-3rd Cycle) cycle, with repeated measures ANOVA test and <italic>Post Hoc</italic> analysis with the Bonferroni method. For clinical efficacy at the same times between subgroups of patients, we used the Kruskal-Wallis non-parametric test and U-Mann&#x02013;Whitney test. ANCOVA was used to verify whether there are relationships between demographic and clinical variables at baseline and percentage improvements in clinical measurement scales.</p></sec></sec><sec sec-type="results" id="sec11"><title>Results</title><sec id="sec12"><title>Participants</title><p>Twelve patients with AChR antibody-positive generalized myasthenia gravis (gMG) were included in this protocol. In addition to collecting demographic and pharmacological data at baseline, we categorized patients based on symptom predominance at T0 using the MG-ADL scale, as outlined in <xref rid="tab1" ref-type="table">Table 1</xref>. For each patient, the scores for the three symptom types&#x02014;Ocular (O), Bulbar (B), and Generalized (G)&#x02014;were divided by their respective maximum possible scores, yielding a percentage impairment for each category. The highest percentage determined the predominant symptom type, classifying patients as predominantly Ocular (pO), predominantly Bulbar (pB), or predominantly Generalized (pG). All 12 patients tested positive for AChR antibodies and were classified as MGFA class II. At baseline (<xref rid="tab2" ref-type="table">Table 2</xref>), three patients were male, with an average age of 58.6&#x0202f;years and an average disease duration of 10.2&#x0202f;years. Their total MG-ADL and QMG scores averaged 7.5 and 12.8 points, respectively. Seven patients had undergone thymectomy, including three with thymoma. Regarding pharmacological therapy, 10 patients were receiving steroids at an average dose of 18.8&#x0202f;mg/day, five were on non-steroidal immunosuppressants (NSIT), and eight were taking acetylcholinesterase inhibitors (AChEI). Four patients were on both steroids and NSIT, and one patient was on AChEI therapy alone. In the 3&#x0202f;months prior to the first Efgartigimod infusion, seven patients required treatment with immunoglobulins or plasmapheresis (IVIg or PLEX). Based on the highest symptom subclass score, four patients each were classified as pO, pB, and pG.</p><table-wrap position="float" id="tab2"><label>Table 2</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Characteristics of the patients at baseline</th><th align="center" valign="top" rowspan="1" colspan="1">mean / <italic>n</italic></th><th align="center" valign="top" rowspan="1" colspan="1">sd / %</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="3" rowspan="1">Demographics</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Male (<italic>n</italic>)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3</td><td align="center" valign="bottom" rowspan="1" colspan="1">25,0%</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Age (y)</td><td align="center" valign="bottom" rowspan="1" colspan="1">58.6</td><td align="center" valign="bottom" rowspan="1" colspan="1">14.0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Disease duration (y)</td><td align="center" valign="bottom" rowspan="1" colspan="1">10.2</td><td align="center" valign="bottom" rowspan="1" colspan="1">6.5</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">MG-ADL total score</td><td align="center" valign="bottom" rowspan="1" colspan="1">7.5</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">QMG Total score</td><td align="center" valign="bottom" rowspan="1" colspan="1">12.8</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.1</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">AChR Antibody levels (nmol/L)</td><td align="center" valign="bottom" rowspan="1" colspan="1">52.7</td><td align="center" valign="bottom" rowspan="1" colspan="1">55.1</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Thymectomy (<italic>n</italic>)</td><td align="center" valign="bottom" rowspan="1" colspan="1">7</td><td align="center" valign="bottom" rowspan="1" colspan="1">58.3%</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Thymoma (<italic>n</italic>)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3</td><td align="center" valign="bottom" rowspan="1" colspan="1">25.0%</td></tr><tr><td align="left" valign="bottom" colspan="3" rowspan="1">MG Therapy</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Any Steroid (<italic>n</italic>)</td><td align="center" valign="bottom" rowspan="1" colspan="1">10</td><td align="center" valign="bottom" rowspan="1" colspan="1">83.3%</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Any Steroid (mg)</td><td align="center" valign="bottom" rowspan="1" colspan="1">18.8</td><td align="center" valign="bottom" rowspan="1" colspan="1">10.5</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Any NSIT (<italic>n</italic>)</td><td align="center" valign="bottom" rowspan="1" colspan="1">5</td><td align="center" valign="bottom" rowspan="1" colspan="1">41.7%</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Any AChEI (<italic>n</italic>)</td><td align="center" valign="bottom" rowspan="1" colspan="1">8</td><td align="center" valign="bottom" rowspan="1" colspan="1">66.7%</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">IVIg /Plex (<italic>n</italic>)</td><td align="center" valign="bottom" rowspan="1" colspan="1">7</td><td align="center" valign="bottom" rowspan="1" colspan="1">58.3%</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Steroid+NSIT (<italic>n</italic>)</td><td align="center" valign="bottom" rowspan="1" colspan="1">4</td><td align="center" valign="bottom" rowspan="1" colspan="1">33.3%</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">AChEI only (<italic>n</italic>)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1</td><td align="center" valign="bottom" rowspan="1" colspan="1">8.3%</td></tr><tr><td align="left" valign="bottom" colspan="3" rowspan="1">Type of patients</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">pO (<italic>n</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="bottom" rowspan="1" colspan="1">33.3%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">pB (<italic>n</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="bottom" rowspan="1" colspan="1">33.3%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">pG (<italic>n</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="bottom" rowspan="1" colspan="1">33,3%</td></tr></tbody></table><table-wrap-foot><p>
<italic>n, frequency; sd, standard deviation; y, yars; NSIT, Non-steroidal immunosuppressants treatments; AChEI, acetylcholinesterase inhibitor; IVIg, immunoglobulins in vein; Plex, plasmapheresis; pO, predominantly Ocular; pB, predominantly Bulbars; pG, predominantly Generalized.</italic>
</p></table-wrap-foot></table-wrap></sec><sec id="sec13"><title>Clinical assessments in all participants</title><p>Twelve patients who started treatment with Efgartigimod completed both the first and second cycles of infusions with a 4-weeks interval between the two cycles as per protocol. Nine patients started the third cycle of therapy with Efgartigimod at an average of 55.1 &#x000b1;&#x0202f;40.0&#x0202f;days after the end of the second cycle and completed it, while only 3 of these patients started the fourth cycle at an average of 35.3 &#x000b1;&#x0202f;5.4&#x0202f;days from the end of the third cycle. Considering all study participants, the means of MG-ADL and QMG were statistically significantly reduced between T0 and T3 of each infusion cycle, considering that in the third cycle for both clinical measurements there were nine patients. The improvements in the MG-ADL and QMG scores were statistically significant both within and between all cycles, as reported in <xref rid="tab3" ref-type="table">Table 3</xref>. In our cohort, baseline AChR antibody levels were markedly higher in patients who had undergone thymectomy compared to those who had not (78.19&#x0202f;&#x000b1;&#x0202f;45 vs. 16.94&#x0202f;&#x000b1;&#x0202f;14&#x0202f;nmol/L, respectively; <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01, <xref rid="fig2" ref-type="fig">Figure 2</xref>).</p><table-wrap position="float" id="tab3"><label>Table 3</label><caption><p>Mean and standard deviation of MG-ADL and QMG scores at the beginning and at the end of each cycle of therapy with Efgartigimod.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="12" rowspan="1">MG-ADL assessment in all patients</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="2" rowspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" colspan="5" rowspan="1"><italic>p</italic> value*</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">MG-ADL</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-3&#x000b0; Cycle</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">mean</td><td align="center" valign="top" rowspan="1" colspan="1">7.5</td><td align="center" valign="top" rowspan="1" colspan="1">4.0</td><td align="center" valign="top" rowspan="1" colspan="1">5.8</td><td align="center" valign="top" rowspan="1" colspan="1">3.1</td><td align="center" valign="top" rowspan="1" colspan="1">7.7</td><td align="center" valign="top" rowspan="1" colspan="1">4.0</td><td align="center" valign="top" rowspan="2" colspan="1">0.007</td><td align="center" valign="top" rowspan="2" colspan="1">0.010</td><td align="center" valign="top" rowspan="2" colspan="1">0.0009</td><td align="center" valign="top" rowspan="2" colspan="1">0.0003</td><td align="center" valign="top" rowspan="2" colspan="1">0.016</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">SD</td><td align="center" valign="top" rowspan="1" colspan="1">2.6</td><td align="center" valign="top" rowspan="1" colspan="1">2.7</td><td align="center" valign="top" rowspan="1" colspan="1">4.1</td><td align="center" valign="top" rowspan="1" colspan="1">1.5</td><td align="center" valign="top" rowspan="1" colspan="1">3.4</td><td align="center" valign="top" rowspan="1" colspan="1">2.8</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="12" rowspan="1">QMG assessment in all patients</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="2" rowspan="1">1&#x000b0; cycle</th><th align="center" valign="top" colspan="2" rowspan="1">2&#x000b0; cycle</th><th align="center" valign="top" colspan="2" rowspan="1">3&#x000b0; cycle</th><th align="center" valign="top" colspan="5" rowspan="1"><italic>p</italic> value*</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">QMG</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-3&#x000b0; Cycle</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">mean</td><td align="center" valign="top" rowspan="1" colspan="1">12.8</td><td align="center" valign="top" rowspan="1" colspan="1">9.2</td><td align="center" valign="top" rowspan="1" colspan="1">12.2</td><td align="center" valign="top" rowspan="1" colspan="1">9.3</td><td align="center" valign="top" rowspan="1" colspan="1">13.0</td><td align="center" valign="top" rowspan="1" colspan="1">10.1</td><td align="center" valign="top" rowspan="2" colspan="1">0.010</td><td align="center" valign="top" rowspan="2" colspan="1">0.035</td><td align="center" valign="top" rowspan="2" colspan="1">0.004</td><td align="center" valign="top" rowspan="2" colspan="1">0.007</td><td align="center" valign="top" rowspan="2" colspan="1">0.043</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">SD</td><td align="center" valign="top" rowspan="1" colspan="1">4.1</td><td align="center" valign="top" rowspan="1" colspan="1">4.7</td><td align="center" valign="top" rowspan="1" colspan="1">6.8</td><td align="center" valign="top" rowspan="1" colspan="1">4.3</td><td align="center" valign="top" rowspan="1" colspan="1">4.4</td><td align="center" valign="top" rowspan="1" colspan="1">4.8</td></tr></tbody></table><table-wrap-foot><p>* Repeated measures ANOVA with <italic>Post Hoc</italic> analysis using Bonferroni method.</p></table-wrap-foot></table-wrap><fig position="float" id="fig2"><label>Figure 2</label><caption><p>Box plot showing anti-AChR antibody levels, expressed as nmol / L, in patients who underwent (positive, +) or not (negative, &#x02212;) thymectomy. ** <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01, U-Mann Whitney for indipendent samples.</p></caption><graphic xlink:href="fneur-16-1555068-g002" position="float"/></fig><p>Covariate analysis showed a significant direct proportional relationship between the level of AChR antibodies at baseline and the improvement in MG-ADL (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.04) and QMG (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01) between the beginning and the end of the first cycle of infusions, while in the second and third cycle this relationship disappeared. Furthermore, patients who had undergone thymectomy despite having had the surgical procedure several years before baseline (median 6.3&#x0202f;years range 4.3&#x02013;8.8), the improvements between the beginning and the end of the first cycle of infusions in MG-ADL were significantly higher with the mean score ranging from 8.0 &#x000b1;&#x0202f;2.8 to 3.1 &#x000b1;&#x0202f;3.0 (which in percentage terms is a change of 62% from baseline <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01, <xref rid="fig3" ref-type="fig">Figure 3</xref>), compared to the other patients who had a mean score ranging from 6.8 &#x000b1;&#x0202f;3.1 to 5.2 &#x000b1;&#x0202f;2.6 (which in percentage terms is a change of 22% from baseline). After the end of the second cycle, the significant difference between the improvements in MG-ADL score between patients with previous thymectomy and the others, disappeared. Improvements in QMG between the start and end of the first infusion cycle in patients with prior thymectomy were significantly greater with a mean score ranging from 13.4 &#x000b1;&#x0202f;4,7 to 7.4 &#x000b1;&#x0202f;4.2 (change of 45% from baseline <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01, <xref rid="fig4" ref-type="fig">Figure 4</xref>), compared to other patients who had a mean score ranging from 12.0 &#x000b1;&#x0202f;5.0 to 11.6 &#x000b1;&#x0202f;4.5 (change of 3.5% from baseline). After the end of the second cycle, this difference remained significantly different, with QMG scores decreasing from 13.4 &#x000b1;&#x0202f;4.7 at baseline to 8.1 &#x000b1;&#x0202f;4.1 at T3 of the second cycle (change of 40% from baseline <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01) for patients with prior thymectomy and from 12.0 &#x000b1;&#x0202f;5.0 at baseline to 10.9 &#x000b1;&#x0202f;4.7 (change of 9% from baseline) at T3 of the second cycle, for patients who had not undergone a previous thymectomy.</p><fig position="float" id="fig3"><label>Figure 3</label><caption><p>Percentage change in mean MG-ADL score and standard deviation from baseline (T0 of the 1st cycle) at the time points of the first two EFG cycles in patients who have or have not previously undergone thymectomy.** <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01 with U-Mann&#x02013;Whitney test.</p></caption><graphic xlink:href="fneur-16-1555068-g003" position="float"/></fig><fig position="float" id="fig4"><label>Figure 4</label><caption><p>Percentage change in mean QMG score and standard deviation from baseline (T0 of the 1st cycle) at the time points of the first two EFG cycles in patients who have or have not previously undergone thymectomy.** <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01 with U-Mann&#x02013;Whitney test.</p></caption><graphic xlink:href="fneur-16-1555068-g004" position="float"/></fig></sec><sec id="sec14"><title>Ocular signs in all patients</title><p>The analysis within and between treatment cycles in ocular signs showed a significant reduction in the average MG-ADL score only between the beginning and the end of the second cycle of infusions. We observed that from baseline to the end of the second and third cycle, the decrease in the MG-ADL score was statistically significant. In QMG, the improvement in ocular signs was significant between baseline and the end of the first and third cycles (<italic>p</italic>&#x0202f;=&#x0202f;0.05, <italic>p</italic>&#x0202f;=&#x0202f;0.01, <xref rid="tab4" ref-type="table">Table 4</xref>).</p><table-wrap position="float" id="tab4"><label>Table 4</label><caption><p>Mean and standard deviation of MG-ADL and QMG scores in Ocular signs at the beginning and at the end of each cycle of therapy with Efgartigimod.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="12" rowspan="1">Ocular signs in MG-ADL assessment in all patients</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="2" rowspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" colspan="5" rowspan="1"><italic>p</italic> value*</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">MG-ADL</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-3&#x000b0; Cycle</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">mean</td><td align="center" valign="top" rowspan="1" colspan="1">2.22</td><td align="center" valign="top" rowspan="1" colspan="1">1.56</td><td align="center" valign="top" rowspan="1" colspan="1">2.00</td><td align="center" valign="top" rowspan="1" colspan="1">1.11</td><td align="center" valign="top" rowspan="1" colspan="1">1.80</td><td align="center" valign="top" rowspan="1" colspan="1">1.40</td><td align="center" valign="top" rowspan="2" colspan="1">0.28</td><td align="center" valign="top" rowspan="2" colspan="1">0.044</td><td align="center" valign="top" rowspan="2" colspan="1">0.34</td><td align="center" valign="top" rowspan="2" colspan="1">0.036</td><td align="center" valign="top" rowspan="2" colspan="1">0.031</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SD</td><td align="center" valign="top" rowspan="1" colspan="1">1.39</td><td align="center" valign="top" rowspan="1" colspan="1">1.51</td><td align="center" valign="top" rowspan="1" colspan="1">1.73</td><td align="center" valign="top" rowspan="1" colspan="1">1.16</td><td align="center" valign="top" rowspan="1" colspan="1">1.44</td><td align="center" valign="top" rowspan="1" colspan="1">1.56</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="12" rowspan="1">Ocular signs in QMG assessment in all patients</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="2" rowspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" colspan="5" rowspan="1"><italic>p</italic> value*</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">QMG</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-3&#x000b0; Cycle</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">mean</td><td align="center" valign="top" rowspan="1" colspan="1">2.88</td><td align="center" valign="top" rowspan="1" colspan="1">1.55</td><td align="center" valign="top" rowspan="1" colspan="1">2.44</td><td align="center" valign="top" rowspan="1" colspan="1">2.00</td><td align="center" valign="top" rowspan="1" colspan="1">2.40</td><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="2" colspan="1">0.050</td><td align="center" valign="top" rowspan="2" colspan="1">0.16</td><td align="center" valign="top" rowspan="2" colspan="1">0.10</td><td align="center" valign="top" rowspan="2" colspan="1">0.19</td><td align="center" valign="top" rowspan="2" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SD</td><td align="center" valign="top" rowspan="1" colspan="1">1.87</td><td align="center" valign="top" rowspan="1" colspan="1">1.23</td><td align="center" valign="top" rowspan="1" colspan="1">2.00</td><td align="center" valign="top" rowspan="1" colspan="1">1.78</td><td align="center" valign="top" rowspan="1" colspan="1">1.23</td><td align="center" valign="top" rowspan="1" colspan="1">1.32</td></tr></tbody></table><table-wrap-foot><p>* Repeated measures ANOVA with <italic>Post Hoc</italic> analysis using Bonferroni method.</p></table-wrap-foot></table-wrap></sec><sec id="sec15"><title>Bulbar signs in all patients</title><p>The analysis within and between treatment cycles in the bulbar signs showed a significant decrease in the average of the MG-ADL score between the beginning and the end of the first and second cycles and also between baseline and the end of the second and third cycles. The mean QMG score of the bulbar signs decreased significantly only between the beginning and the end of the first cycle and also between baseline and the end of the second and third cycle (<italic>p</italic>&#x0202f;=&#x0202f;0.041, <italic>p</italic>&#x0202f;=&#x0202f;0.034, <xref rid="tab5" ref-type="table">Table 5</xref>).</p><table-wrap position="float" id="tab5"><label>Table 5</label><caption><p>Mean and standard deviation of MG-ADL and QMG scores in Bulbar signs at the beginning and at the end of each cycle of therapy with Efgartigimod.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="12" rowspan="1">Bulbar signs in MG-ADL assessment in all patients</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="2" rowspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" colspan="5" rowspan="1"><italic>p</italic> value</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">MG-ADL</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-3&#x000b0; Cycle</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">mean</td><td align="center" valign="top" rowspan="1" colspan="1">3.88</td><td align="center" valign="top" rowspan="1" colspan="1">1.13</td><td align="center" valign="top" rowspan="1" colspan="1">2.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.88</td><td align="center" valign="top" rowspan="1" colspan="1">3.20</td><td align="center" valign="top" rowspan="1" colspan="1">1.20</td><td align="center" valign="top" rowspan="2" colspan="1">0.030</td><td align="center" valign="top" rowspan="2" colspan="1">0.010</td><td align="center" valign="top" rowspan="2" colspan="1">0.11</td><td align="center" valign="top" rowspan="2" colspan="1">0.012</td><td align="center" valign="top" rowspan="2" colspan="1">0.021</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SD</td><td align="center" valign="top" rowspan="1" colspan="1">2.00</td><td align="center" valign="top" rowspan="1" colspan="1">1.66</td><td align="center" valign="top" rowspan="1" colspan="1">1.23</td><td align="center" valign="top" rowspan="1" colspan="1">1.88</td><td align="center" valign="top" rowspan="1" colspan="1">1.58</td><td align="center" valign="top" rowspan="1" colspan="1">1.54</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="12" rowspan="1">Bulbar signs in QMG assessment in all patients</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="2" rowspan="1">1&#x000b0; cycle</th><th align="center" valign="top" colspan="2" rowspan="1">2&#x000b0; cycle</th><th align="center" valign="top" colspan="2" rowspan="1">3&#x000b0; cycle</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">QMG</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-3&#x000b0; Cycle</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">mean</td><td align="center" valign="top" rowspan="1" colspan="1">2.50</td><td align="center" valign="top" rowspan="1" colspan="1">0.50</td><td align="center" valign="top" rowspan="1" colspan="1">1.43</td><td align="center" valign="top" rowspan="1" colspan="1">0.86</td><td align="center" valign="top" rowspan="1" colspan="1">2.40</td><td align="center" valign="top" rowspan="1" colspan="1">0.60</td><td align="center" valign="top" rowspan="2" colspan="1">0.018</td><td align="center" valign="top" rowspan="2" colspan="1">0.10</td><td align="center" valign="top" rowspan="2" colspan="1">0.12</td><td align="center" valign="top" rowspan="2" colspan="1">0.041</td><td align="center" valign="top" rowspan="2" colspan="1">0.034</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SD</td><td align="center" valign="top" rowspan="1" colspan="1">1.79</td><td align="center" valign="top" rowspan="1" colspan="1">1.39</td><td align="center" valign="top" rowspan="1" colspan="1">1.49</td><td align="center" valign="top" rowspan="1" colspan="1">1.43</td><td align="center" valign="top" rowspan="1" colspan="1">2.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.83</td></tr></tbody></table><table-wrap-foot><p>* Repeated measures ANOVA with <italic>Post Hoc</italic> analysis using Bonferroni method.</p></table-wrap-foot></table-wrap></sec><sec id="sec16"><title>Generalizated signs in all patients</title><p>The analysis within and between treatment cycles in generalized signs showed a significant decrease in the mean MG-ADL score only in the first infusion cycle. The average QMG score of generalized signs showed a significant decrease between T0 and T3 in the second cycle and between baseline and T3 of second cycle (<italic>p</italic>&#x0202f;=&#x0202f;0.016, <xref rid="tab6" ref-type="table">Table 6</xref>).</p><table-wrap position="float" id="tab6"><label>Table 6</label><caption><p>Mean and standard deviation of MG-ADL and QMG scores in Generalized signs at the beginning and at the end of each cycle of therapy with Efgartigimod.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="12" rowspan="1">Generalized signs in MG-ADL assessment</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="2" rowspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">3&#x000b0; Cycle</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">MG-ADL</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-3&#x000b0; Cycle</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">mean</td><td align="center" valign="top" rowspan="1" colspan="1">3.20</td><td align="center" valign="top" rowspan="1" colspan="1">1.90</td><td align="center" valign="top" rowspan="1" colspan="1">3.40</td><td align="center" valign="top" rowspan="1" colspan="1">2.20</td><td align="center" valign="top" rowspan="1" colspan="1">5.25</td><td align="center" valign="top" rowspan="1" colspan="1">3.00</td><td align="center" valign="top" rowspan="2" colspan="1">0.03</td><td align="center" valign="top" rowspan="2" colspan="1">0.07</td><td align="center" valign="top" rowspan="2" colspan="1">0.11</td><td align="center" valign="top" rowspan="2" colspan="1">0.10</td><td align="center" valign="top" rowspan="2" colspan="1">0.45</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SD</td><td align="center" valign="top" rowspan="1" colspan="1">1.44</td><td align="center" valign="top" rowspan="1" colspan="1">1.73</td><td align="center" valign="top" rowspan="1" colspan="1">2.11</td><td align="center" valign="top" rowspan="1" colspan="1">1.89</td><td align="center" valign="top" rowspan="1" colspan="1">2.30</td><td align="center" valign="top" rowspan="1" colspan="1">2.07</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="12" rowspan="1">Generalized signs in QMG assessment</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="2" rowspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" colspan="2" rowspan="1">3&#x000b0; Cycle</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">QMG</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">T0</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">3&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-2&#x000b0; Cycle</th><th align="center" valign="top" rowspan="1" colspan="1">1&#x000b0;-3&#x000b0; Cycle</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">mean</td><td align="center" valign="top" rowspan="1" colspan="1">9.22</td><td align="center" valign="top" rowspan="1" colspan="1">7.89</td><td align="center" valign="top" rowspan="1" colspan="1">9.11</td><td align="center" valign="top" rowspan="1" colspan="1">7.22</td><td align="center" valign="top" rowspan="1" colspan="1">9.66</td><td align="center" valign="top" rowspan="1" colspan="1">9.50</td><td align="center" valign="top" rowspan="2" colspan="1">0.065</td><td align="center" valign="top" rowspan="2" colspan="1">0.016</td><td align="center" valign="top" rowspan="2" colspan="1">0.89</td><td align="center" valign="top" rowspan="2" colspan="1">0.020</td><td align="center" valign="top" rowspan="2" colspan="1">0.87</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SD</td><td align="center" valign="top" rowspan="1" colspan="1">2.54</td><td align="center" valign="top" rowspan="1" colspan="1">3.55</td><td align="center" valign="top" rowspan="1" colspan="1">5.28</td><td align="center" valign="top" rowspan="1" colspan="1">3.99</td><td align="center" valign="top" rowspan="1" colspan="1">3.80</td><td align="center" valign="top" rowspan="1" colspan="1">4.70</td></tr></tbody></table><table-wrap-foot><p>* Repeated measures ANOVA with <italic>Post Hoc</italic> analysis using Bonferron method.</p></table-wrap-foot></table-wrap></sec><sec id="sec17"><title>MG-ADL and QMG subdomains for type of patients</title><p>We observed that the percentage of improvement of MG-ADL from baseline to T3 of second cycle, was not different between the patient types of patients, while there was a significant difference in the percentages of improvement of QMG. In the pO patient group, the percentage of improvement of the individual subdomains of QMG, although with a small sample size for each subdomain, showed differeces, with Generalized Signs being the least responsive symptomatology to treatment (<xref rid="tab7" ref-type="table">Table 7</xref>).</p><table-wrap position="float" id="tab7"><label>Table 7</label><caption><p>Percentage (%) of improvement in MG-ADL and QMG by patient type and symptom subdomain (sd) * Kruskal-Wallis non-parametric test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="3" rowspan="1">Prevalent ocular patients</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" valign="top" colspan="3" rowspan="1">Prevalent bulbar patients</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" valign="top" colspan="3" rowspan="1">Prevalent generalizated patients</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="3" colspan="1">% improvement MG-ADL</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">59.6 (31)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">50.11 (40)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">61.02 (48)</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.89*</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Ocular signs</td><td align="center" valign="top" rowspan="1" colspan="1">Bulbar signs</td><td align="center" valign="top" rowspan="1" colspan="1">Generalized signs</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Ocular signs</td><td align="center" valign="top" rowspan="1" colspan="1">Bulbar signs</td><td align="center" valign="top" rowspan="1" colspan="1">Generalized signs</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Ocular signs</td><td align="center" valign="top" rowspan="1" colspan="1">Bulbar signs</td><td align="center" valign="top" rowspan="1" colspan="1">Generalized signs</td><td rowspan="1" colspan="1"/></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">55 (33)</td><td align="center" valign="top" rowspan="1" colspan="1">39 (31)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (28)</td><td align="center" valign="top" rowspan="1" colspan="1">0.74**</td><td align="center" valign="top" rowspan="1" colspan="1">44 (48)</td><td align="center" valign="top" rowspan="1" colspan="1">49 (33)</td><td align="center" valign="top" rowspan="1" colspan="1">57 (31)</td><td align="center" valign="top" rowspan="1" colspan="1">0.67**</td><td align="center" valign="top" rowspan="1" colspan="1">39 (53)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (41)</td><td align="center" valign="top" rowspan="1" colspan="1">65 (44)</td><td align="center" valign="top" rowspan="1" colspan="1">0.39**</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="3" rowspan="1">Prevalent ocular patients</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" valign="top" colspan="3" rowspan="1">Prevalent bulbar patients</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" valign="top" colspan="3" rowspan="1">Prevalent generalizated patients</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="3" colspan="1">% improvement QMG</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">13.42 (19)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">37.44 (20)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">28.32 (51)</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.03*</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Ocular signs</td><td align="center" valign="top" rowspan="1" colspan="1">Bulbar signs</td><td align="center" valign="top" rowspan="1" colspan="1">Generalized signs</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Ocular signs</td><td align="center" valign="top" rowspan="1" colspan="1">Bulbar signs</td><td align="center" valign="top" rowspan="1" colspan="1">Generalized signs</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Ocular signs</td><td align="center" valign="top" rowspan="1" colspan="1">Bulbar signs</td><td align="center" valign="top" rowspan="1" colspan="1">Generalized signs</td><td rowspan="1" colspan="1"/></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">44 (22)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (27)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01**</td><td align="center" valign="top" rowspan="1" colspan="1">32 (15)</td><td align="center" valign="top" rowspan="1" colspan="1">46 (32)</td><td align="center" valign="top" rowspan="1" colspan="1">39 (22)</td><td align="center" valign="top" rowspan="1" colspan="1">0.45**</td><td align="center" valign="top" rowspan="1" colspan="1">59 (41)</td><td align="center" valign="top" rowspan="1" colspan="1">78 (76)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (37)</td><td align="center" valign="top" rowspan="1" colspan="1">0.34**</td></tr></tbody></table><table-wrap-foot><p>** U-Mann&#x02013;Whitney test for independent samples.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="sec18"><title>Discussion</title><p>During the Generative protocol, we treated 12 patients with AChR-positive generalized myasthenia gravis (gMG), all of whom received two complete cycles of Efgartigimod infusions between August 2023 and August 2024. Among these, nine patients completed a third cycle, and four continued with therapy, undergoing up to six cycles almost chronically, in line with the EAP protocol. Due to the limited number of patients beyond the third cycle, we focused our analysis on data from baseline to the end of the third cycle. Our study aimed to identify the clinical characteristics of patients who experienced the best outcomes with Efgartigimod, to guide future treatment decisions. Across all 12 patients, we observed strong evidence of the therapy&#x02019;s effectiveness, with significant improvements in MG-ADL and QMG scores from baseline to the end of every cycles. Efgartigimod, an FcRn antagonist, induces a profound and sustained reduction in serum IgG levels, significantly alleviating symptoms of gMG (<xref rid="ref12" ref-type="bibr">12</xref>). In our cohort, no adverse effects were observed. Clinical improvements correlated positively with baseline AChR antibody levels, particularly during the first cycle, for both MG-ADL and QMG assessments. The use of therapeutic molecules targeting the neonatal Fc receptor (FcRn) aims at the selective removal of immunoglobulin G (IgG), a process that is also widely performed by plasmapheresis in patients with myasthenia gravis (MG). It has been observed that high levels of anti-AChR antibodies at baseline are one of the favorable prognostic factors for a better response to treatment (<xref rid="ref12" ref-type="bibr">12</xref>). In a 2022 review, the authors questioned the correlation between autoantibody levels and disease severity in individuals with myasthenia gravis (MG) (<xref rid="ref13" ref-type="bibr">13</xref>) and in most of the studies reviewed, positive and significant correlations between autoantibody levels and clinical improvement were described (<xref rid="ref13" ref-type="bibr">13</xref>). Another recent review (<xref rid="ref14" ref-type="bibr">14</xref>) corroborates these findings, noting that the highest antibody titers occur in patients with thymic hyperplasia, followed by intermediate levels in those with thymoma, and lower levels in individuals with atrophic or normal thymus. Although antibody levels were correlated with clinical improvements in the first cycle, this relationship decreased in subsequent cycles. This trend may reflect a possible reduction in antibody levels after initial treatments with Efgartigimod (<xref rid="ref15" ref-type="bibr">15</xref>) and similar therapies (<xref rid="ref16" ref-type="bibr">16</xref>). Patients who had undergone thymectomy, even if the surgical procedure had been performed at least 4.3&#x0202f;years before and the positive effect of thymic surgery occurs within a maximum of 1&#x02013;2&#x0202f;years from the event (<xref rid="ref17" ref-type="bibr">17</xref>), seemed to benefit more from Efgartigimod, with improvements in MG-ADL scores after the first cycle and QMG improvements sustained also during the second cycle appeared to benefit more from Efgartigimod, with greater improvements in MG-ADL scores after the first cycle and sustained QMG improvements through the second cycle. This may be linked to the inflamed thymus in myasthenia gravis, particularly in cases of thymoma, which is often infiltrated with B cells and Th cells, including Th-GM and Th-CD103 subtypes (<xref rid="ref18" ref-type="bibr">18</xref>). These T cells, known to drive chronic pathogenic antibody production, can persist even after thymectomy. Long-term studies suggest that thymectomy does not fully resolve symptoms, particularly in younger patients, who may continue to struggle with muscle weakness and fatigue (<xref rid="ref19" ref-type="bibr">19</xref>, <xref rid="ref20" ref-type="bibr">20</xref>). In these cases, Efgartigimod&#x02019;s mechanism&#x02014;blocking FcRn and reducing pathogenic antibodies&#x02014;might be especially valuable. Our findings also showed significant improvements across all MG-ADL subdomains (ocular, bulbar, generalized) and in QMG composite scores. However, prior studies have reported varying degrees of improvement in specific subdomains depending on the treatment (<xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref21" ref-type="bibr">21</xref>). In our cohort, patients with predominantly ocular symptoms (pO) showed less improvement (13.42% in QMG scores) compared to those with bulbar (pB, 38.44%) or generalized symptoms (pG, 71.89%). This suggests that pO patients may respond less robustly to Efgartigimod, potentially due to distinct underlying mechanisms or reduced involvement of pathogenic antibodies in ocular symptoms (<xref rid="ref22" ref-type="bibr">22</xref>, <xref rid="ref23" ref-type="bibr">23</xref>). Although our sample is small, our real-world observations suggest that patients with elevated AChR antibody titers and a history of thymectomy may respond more favorably to Efgartigimod. The relationship between the predominance of non-ocular symptoms and a better clinical outcome, while observed, does not allow for any significant conclusions given the small number of patients in the pO, pB, and pG subgroups. The main limitation of this study is undoubtedly the small number of participants, which makes the results less robust, although it provides significant observations that may encourage future research, especially real world, on potentially more treatment-responsive target patients, the long-term effects of Efgartigimod, and the optimization of dosing regimens. Furthermore, it should be noted that participants presented moderate weakness at the beginning of the study (MGFA class II), which may have influenced the clinical observations, especially in evaluating the responses of the patient subgroups given the small sample sizes. Finally, given the results of previous clinical trials and in the absence of a control group, assessments of the response to Efgartigimod therapy must be considered with due caution, especially in the early stages of treatment (<xref rid="ref24" ref-type="bibr">24</xref>, <xref rid="ref25" ref-type="bibr">25</xref>).</p></sec></body><back><ack><p>We express our gratitude to all the nursing figures of the Day Hospital of the Neurology Department of the Papa Giovanni XXIII Hospital, for the valuable work done with regard to the patients included in this study and beyond.</p></ack><fn-group><title>Abbreviations</title><fn fn-type="abbr"><p>gMG, generalized Myasthenia Gravis; FcRn, Neonatal Fc Receptor; EAP, Expanded Access Program; EFG, Efgartigimod; AChR, Acetylcholine Receptor; MGFA, Myasthenia Gravis Foundation of America; MG-ADL, Myasthenia Gravis Activity of Daily Living; QMG, Quantitative Myasthenia Gravis; AChEI, Acetylcholinesterase Inhibitor; NSIT, Non-Steroidal Immunosuppressant Treatments; pO, patients predominantly Ocular; pB, patients predominantly Bulbar; pG, patients predominantly Generalized; IVIg, Intravenous Immunoglobulin; Plex, Plasmapheresis.</p></fn></fn-group><sec sec-type="data-availability" id="sec19"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="sec20"><title>Ethics statement</title><p>The studies involving humans were approved by Comitato Etico ASST Papa Giovanni XXIII. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="sec21"><title>Author contributions</title><p>MS: Conceptualization, Investigation, Methodology, Project administration, Supervision, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. PP: Conceptualization, Data curation, Formal analysis, Methodology, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. GC: Conceptualization, Investigation, Methodology, Supervision, Writing &#x02013; review &#x00026; editing. EA: Conceptualization, Investigation, Methodology, Supervision, Writing &#x02013; review &#x00026; editing. SM: Writing &#x02013; review &#x00026; editing. FM: Writing &#x02013; review &#x00026; editing. DA: Conceptualization, Project administration, Supervision, Validation, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="sec23"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec24"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="sec25"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyka</surname><given-names>KV</given-names></name><name><surname>Brachman</surname><given-names>DB</given-names></name><name><surname>Pestronk</surname><given-names>A</given-names></name><name><surname>Kao</surname><given-names>I</given-names></name></person-group>. <article-title>Myasthenia gravis: passive transfer from man to mouse</article-title>. <source>Science</source>. (<year>1975</year>) <volume>190</volume>:<fpage>397</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1179220</pub-id>, PMID: <pub-id pub-id-type="pmid">1179220</pub-id>
</mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulrichts</surname><given-names>P</given-names></name><name><surname>Guglietta</surname><given-names>A</given-names></name><name><surname>Dreier</surname><given-names>T</given-names></name><name><surname>van Bragt</surname><given-names>T</given-names></name><name><surname>Hanssens</surname><given-names>V</given-names></name><name><surname>Hofman</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans</article-title>. <source>J Clin Invest</source>. (<year>2018</year>) <volume>128</volume>:<fpage>4372</fpage>&#x02013;<lpage>86</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI97911</pub-id>, PMID: <pub-id pub-id-type="pmid">30040076</pub-id>
</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhandari</surname><given-names>V</given-names></name><name><surname>Bril</surname><given-names>V</given-names></name></person-group>. <article-title>FcRN receptor antagonists in the management of myasthenia gravis</article-title>. <source>Front Neurol</source>. (<year>2023</year>) <volume>14</volume>:<fpage>1229112</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2023.1229112</pub-id>, PMID: <pub-id pub-id-type="pmid">37602255</pub-id>
</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roopenian</surname><given-names>DC</given-names></name><name><surname>Akilesh</surname><given-names>S</given-names></name></person-group>. <article-title>FcRn: the neonatal fc receptor comes of age</article-title>. <source>Nat Rev Immunol</source>. (<year>2007</year>) <volume>7</volume>:<fpage>715</fpage>&#x02013;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri2155</pub-id>, PMID: <pub-id pub-id-type="pmid">17703228</pub-id>
</mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>J</given-names></name><name><surname>Bril</surname><given-names>V</given-names></name><name><surname>Vu</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Long-term safety, tolerability and efficacy of efgartigimod in patients with generalized myasthenia gravis: interim results of the ADAPT+ study</article-title>. <source>Neurology</source>. (<year>2022</year>) <volume>99</volume>:<fpage>e2</fpage>. doi: <pub-id pub-id-type="doi">10.1212/01.wnl.0000903308.81107.e2</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaretzki</surname><given-names>A</given-names></name><name><surname>Barohn</surname><given-names>RJ</given-names></name><name><surname>Ernstoff</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America</article-title>. <source>Neurology</source>. (<year>2000</year>) <volume>55</volume>:<fpage>16</fpage>&#x02013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1212/wnl.55.1.16</pub-id>, PMID: <pub-id pub-id-type="pmid">10891897</pub-id>
</mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muppidi</surname><given-names>S</given-names></name><name><surname>Silvestri</surname><given-names>NJ</given-names></name><name><surname>Tan</surname><given-names>R</given-names></name><name><surname>Riggs</surname><given-names>K</given-names></name><name><surname>Leighton</surname><given-names>T</given-names></name><name><surname>Phillips</surname><given-names>GA</given-names></name></person-group>. <article-title>Utilization of MG-ADL in myasthenia gravis clinical research and care</article-title>. <source>Muscle Nerve</source>. (<year>2022</year>) <volume>65</volume>:<fpage>630</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mus.27476</pub-id>, PMID: <pub-id pub-id-type="pmid">34989427</pub-id>
</mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedlack</surname><given-names>RS</given-names></name><name><surname>Simel</surname><given-names>DL</given-names></name><name><surname>Bosworth</surname><given-names>H</given-names></name><name><surname>Samsa</surname><given-names>G</given-names></name><name><surname>Tucker-Lipscomb</surname><given-names>B</given-names></name><name><surname>Sanders</surname><given-names>DB</given-names></name></person-group>. <article-title>Quantitative myasthenia gravis: assessment of responsiveness and longitudinal validity</article-title>. <source>Neurology</source>. (<year>2005</year>) <volume>64</volume>:<fpage>1968</fpage>&#x02013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1212/01.WNL.0000163988.28892.79</pub-id>, PMID: <pub-id pub-id-type="pmid">15955957</pub-id>
</mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Garcia</surname><given-names>AM</given-names></name><name><surname>Santoro</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>McDonnell</surname><given-names>K</given-names></name><name><surname>Dumont</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade</article-title>. <source>J Immunol</source>. (<year>2007</year>) <volume>178</volume>:<fpage>5390</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.178.8.5390</pub-id><pub-id pub-id-type="pmid">17404325</pub-id>
</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sesarman</surname><given-names>A</given-names></name><name><surname>Sitaru</surname><given-names>AG</given-names></name><name><surname>Olaru</surname><given-names>F</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Sitaru</surname><given-names>C</given-names></name></person-group>. <article-title>Neonatal fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita</article-title>. <source>J Mol Med</source>. (<year>2008</year>) <volume>86</volume>:<fpage>951</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00109-008-0366-7</pub-id><pub-id pub-id-type="pmid">18542899</pub-id>
</mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bril</surname><given-names>V</given-names></name><name><surname>Howard</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Karam</surname><given-names>C</given-names></name><name><surname>De Bleecker</surname><given-names>JL</given-names></name><name><surname>Murai</surname><given-names>H</given-names></name><name><surname>Utsugisawa</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study</article-title>. <source>Eur J Neurol</source>. (<year>2024</year>) <volume>31</volume>:<fpage>e16098</fpage>. doi: <pub-id pub-id-type="doi">10.1111/ene.16098</pub-id>, PMID: <pub-id pub-id-type="pmid">37843174</pub-id>
</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Therapeutic plasma exchange in AChR-ab positive generalized myasthenia gravis: a real world study about its early response</article-title>. <source>J Inflamm Res</source>. (<year>2024</year>) <volume>17</volume>:<fpage>2299</fpage>&#x02013;<lpage>308</lpage>. doi: <pub-id pub-id-type="doi">10.2147/JIR.S455104</pub-id>, PMID: <pub-id pub-id-type="pmid">38645879</pub-id>
</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meisel</surname><given-names>A</given-names></name><name><surname>Baggi</surname><given-names>F</given-names></name><name><surname>Behin</surname><given-names>A</given-names></name><name><surname>Evoli</surname><given-names>A</given-names></name><name><surname>Kostera-Pruszczyk</surname><given-names>A</given-names></name><name><surname>Mantegazza</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal</article-title>. <source>Eur J Neurol</source>. (<year>2023</year>) <volume>30</volume>:<fpage>266</fpage>&#x02013;<lpage>82</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ene.15565</pub-id>. PMID: 36094738, PMID: <pub-id pub-id-type="pmid">36094738</pub-id>
</mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>GZ</given-names></name><name><surname>Lo</surname><given-names>YL</given-names></name></person-group>. <article-title>Correlation between acetylcholine receptor antibody levels and thymic pathology in myasthenia gravis: a review</article-title>. <source>J Clin Neuromuscul Dis</source>. (<year>2013</year>) <volume>14</volume>:<fpage>209</fpage>&#x02013;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1097/CND.0b013e31828a0090</pub-id><pub-id pub-id-type="pmid">23703018</pub-id>
</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Bril</surname><given-names>V</given-names></name><name><surname>Burns</surname><given-names>TM</given-names></name><name><surname>Mantegazza</surname><given-names>R</given-names></name><name><surname>Bilinska</surname><given-names>M</given-names></name><name><surname>Szczudlik</surname><given-names>A</given-names></name></person-group>. <article-title>Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis</article-title>. <source>Neurology</source>. (<year>2019</year>) <volume>92</volume>:<fpage>e2661</fpage>&#x02013;<lpage>73</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000007600</pub-id>, PMID: <pub-id pub-id-type="pmid">31118245</pub-id>
</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>S</given-names></name><name><surname>Vickers</surname><given-names>A</given-names></name></person-group>. <article-title>Eculizumab in myasthenia gravis: a review</article-title>. <source>Saudi J Ophthalmol</source>. (<year>2024</year>) <volume>38</volume>:<fpage>34</fpage>&#x02013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.4103/sjopt.sjopt_74_23</pub-id>, PMID: <pub-id pub-id-type="pmid">38628404</pub-id>
</mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aljaafari</surname><given-names>D</given-names></name><name><surname>Ishaque</surname><given-names>N</given-names></name></person-group>. <article-title>Thymectomy in myasthenia gravis: a narrative review</article-title>. <source>Saudi J Med Med Sci</source>. (<year>2022</year>) <volume>10</volume>:<fpage>97</fpage>&#x02013;<lpage>104</lpage>. doi: <pub-id pub-id-type="doi">10.4103/sjmms.sjmms_80_22</pub-id>, PMID: <pub-id pub-id-type="pmid">35602390</pub-id>
</mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingelfinger</surname><given-names>F</given-names></name><name><surname>Krishnarajah</surname><given-names>S</given-names></name><name><surname>Kramer</surname><given-names>M</given-names></name><name><surname>Utz</surname><given-names>SG</given-names></name><name><surname>Galli</surname><given-names>E</given-names></name><name><surname>Lutz</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature</article-title>. <source>Acta Neuropathol</source>. (<year>2021</year>) <volume>141</volume>:<fpage>901</fpage>&#x02013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00401-021-02299-y</pub-id>, PMID: <pub-id pub-id-type="pmid">33774709</pub-id>
</mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menghesha</surname><given-names>H</given-names></name><name><surname>Schroeter</surname><given-names>M</given-names></name><name><surname>Nelke</surname><given-names>C</given-names></name><name><surname>Ruck</surname><given-names>T</given-names></name><name><surname>Schlachtenberger</surname><given-names>G</given-names></name><name><surname>Welskop</surname><given-names>C</given-names></name></person-group>. <article-title>The impact of thymectomy in subgroups of myasthenia gravis patients: a single center longitudinal observation</article-title>. <source>Neurol Res Pract</source>. (<year>2023</year>) <volume>5</volume>:<fpage>24</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s42466-023-00252-w</pub-id>, PMID: <pub-id pub-id-type="pmid">37316910</pub-id>
</mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Hoehn</surname><given-names>KB</given-names></name><name><surname>Lee</surname><given-names>CS</given-names></name><etal/></person-group>. <article-title>Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2020</year>) <volume>117</volume>:<fpage>30649</fpage>&#x02013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2007206117</pub-id>, PMID: <pub-id pub-id-type="pmid">33199596</pub-id>
</mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>C</given-names></name><name><surname>Bril</surname><given-names>V</given-names></name><name><surname>Kapral</surname><given-names>M</given-names></name><name><surname>Kulkarni</surname><given-names>AV</given-names></name><name><surname>Davis</surname><given-names>AM</given-names></name></person-group>. <article-title>Myasthenia gravis impairment index: responsiveness, meaningful change, and relative efficiency</article-title>. <source>Neurology</source>. (<year>2017</year>) <volume>89</volume>:<fpage>2357</fpage>&#x02013;<lpage>64</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000004676</pub-id>, PMID: <pub-id pub-id-type="pmid">29101274</pub-id>
</mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Inaba</surname><given-names>Y</given-names></name><name><surname>Nakazawa</surname><given-names>Y</given-names></name><name><surname>Omata</surname><given-names>T</given-names></name><name><surname>Akasaka</surname><given-names>M</given-names></name><name><surname>Shirai</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Reduction in peripheral regulatory T cell population in childhood ocular type myasthenia gravis</article-title>. <source>Brain Dev</source>. (<year>2015</year>) <volume>37</volume>:<fpage>808</fpage>&#x02013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.braindev.2014.12.007</pub-id>, PMID: <pub-id pub-id-type="pmid">25563663</pub-id>
</mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohler</surname><given-names>S</given-names></name><name><surname>Keil</surname><given-names>TO</given-names></name><name><surname>Swierzy</surname><given-names>M</given-names></name><name><surname>Hoffmann</surname><given-names>S</given-names></name><name><surname>Schaffert</surname><given-names>H</given-names></name><name><surname>Ismail</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients</article-title>. <source>J Neuroimmunol</source>. (<year>2013</year>) <volume>264</volume>:<fpage>114</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jneuroim.2013.09.006</pub-id>, PMID: <pub-id pub-id-type="pmid">24099983</pub-id>
</mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Bril</surname><given-names>V</given-names></name><name><surname>Vu</surname><given-names>T</given-names></name><name><surname>Karam</surname><given-names>C</given-names></name><name><surname>Peric</surname><given-names>S</given-names></name><name><surname>Margania</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial</article-title>. <source>Lancet Neurol</source>. (<year>2021</year>) <volume>20</volume>:<fpage>526</fpage>&#x02013;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(21)00159-9</pub-id>, PMID: <pub-id pub-id-type="pmid">34146511</pub-id>
</mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Bril</surname><given-names>V</given-names></name><name><surname>Vu</surname><given-names>T</given-names></name><name><surname>Karam</surname><given-names>C</given-names></name><name><surname>Peric</surname><given-names>S</given-names></name><name><surname>De Bleecker</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis</article-title>. <source>Front Neurol</source>. (<year>2024</year>) <volume>14</volume>:<fpage>1284444</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2023.1284444</pub-id>, PMID: <pub-id pub-id-type="pmid">38318236</pub-id>
</mixed-citation></ref></ref-list></back></article>